Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

2.7K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.7K
Dementia01:30

Dementia

597
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
597
Psychoneuroimmunology: Diabetes and Cancer01:19

Psychoneuroimmunology: Diabetes and Cancer

540
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
540
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

716
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
716

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Wildfires, brain health and mental health: A narrative review on the physiological and psychological interplay.

The Science of the total environment·2026
Same author

Microglial heterogeneity: influence of human 2D, 3D, and co-culture models on gene expression and immune function.

Frontiers in cellular neuroscience·2026
Same author

The impact of military occupational combustion smoke inhalation on neuroinflammation and brain health.

Neurotoxicology·2026
Same author

Drug repurposing candidates for amyotrophic lateral sclerosis using common and rare genetic variants.

Brain communications·2025
Same author

Exploring a patient-specific in vitro pipeline for stratification and drug response prediction of microglia-based therapeutics.

Scientific reports·2025
Same author

The Role of Air Pollution and Olfactory Dysfunction in Alzheimer's Disease Pathogenesis.

Biomedicines·2025

Related Experiment Video

Updated: Feb 23, 2026

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
06:52

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

Published on: April 28, 2023

2.0K

Copper and Alzheimer's Disease.

Zoe K Mathys1, Anthony R White2,3,4

  • 1Department of Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.

Advances in Neurobiology
|September 11, 2017
PubMed
Summary

Alzheimer's disease involves abnormal copper (Cu) levels and accumulation in the brain, potentially causing neurotoxicity. Research is exploring Cu regulation as a therapeutic strategy for this neurodegenerative condition.

Keywords:
Alzheimer’s diseaseAmyloid precursor proteinCeruloplasminClioquinolCopperNeuroinflammationPBT-2Reactive oxygen speciesTau

More Related Videos

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
07:32

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining

Published on: May 23, 2025

1.3K
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

37.5K

Related Experiment Videos

Last Updated: Feb 23, 2026

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
06:52

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

Published on: April 28, 2023

2.0K
Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
07:32

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining

Published on: May 23, 2025

1.3K
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

37.5K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pathology

Background:

  • Alzheimer's disease (AD) is a leading cause of adult neurodegeneration, marked by cognitive decline.
  • Key hallmarks include amyloid plaques, neurofibrillary tangles, neuroinflammation, oxidative stress, and disrupted biometal homeostasis.
  • Altered copper (Cu) levels and localization are observed in AD brains, with Cu accumulating in amyloid deposits.

Purpose of the Study:

  • To review the association between copper (Cu) and Alzheimer's disease (AD) pathology.
  • To explore how Cu dysregulation contributes to neurodegeneration in AD.
  • To examine therapeutic strategies targeting Cu homeostasis in AD.

Main Methods:

  • Review of existing literature on copper's role in Alzheimer's disease.
  • Analysis of neuropathological findings related to copper in AD brain.
  • Examination of studies on copper metabolism and neuroinflammation in AD.

Main Results:

  • Copper (Cu) binds to amyloid precursor protein (APP) and amyloid beta (Aβ), potentially generating reactive oxygen species and neurotoxicity.
  • Systemic changes in Cu metabolism are evident in AD patients.
  • Altered copper levels may influence neuroinflammatory processes in AD.

Conclusions:

  • Copper dysregulation is implicated in Alzheimer's disease pathogenesis.
  • Targeting copper levels and interactions with copper-binding proteins presents a potential therapeutic avenue.
  • Further research into Cu homeostasis is crucial for developing effective AD interventions.